These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 9182833)
1. Disposition of leucovorin and its metabolites in dietary folic acid-deplete mice - comparison between tumor, liver, and plasma. Raghunathan K; Schmitz JC; Priest DG Cancer Chemother Pharmacol; 1997; 40(2):126-30. PubMed ID: 9182833 [TBL] [Abstract][Full Text] [Related]
2. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Schmitz JC; Grindey GB; Schultz RM; Priest DG Biochem Pharmacol; 1994 Jul; 48(2):319-25. PubMed ID: 8053927 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. Priest DG; Schmitz JC; Bunni MA; Stuart RK J Natl Cancer Inst; 1991 Dec; 83(24):1806-12. PubMed ID: 1744924 [TBL] [Abstract][Full Text] [Related]
4. Modulation of fluorouracil antitumor activity by folic acid in a murine model system. Raghunathan K; Priest DG Biochem Pharmacol; 1999 Sep; 58(5):835-9. PubMed ID: 10449194 [TBL] [Abstract][Full Text] [Related]
5. Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice. Bunni MA; Sirotnak FM; Otter GM; Priest DG Cancer Chemother Pharmacol; 1994; 34(6):455-8. PubMed ID: 7923554 [TBL] [Abstract][Full Text] [Related]
6. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Raghunathan K; Schmitz JC; Priest DG Biochem Pharmacol; 1997 Apr; 53(8):1197-202. PubMed ID: 9175725 [TBL] [Abstract][Full Text] [Related]
7. Disposition of folic acid and its metabolites: a comparison with leucovorin. Schmitz JC; Stuart RK; Priest DG Clin Pharmacol Ther; 1994 May; 55(5):501-8. PubMed ID: 8181194 [TBL] [Abstract][Full Text] [Related]
8. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838 [TBL] [Abstract][Full Text] [Related]
9. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo. Priest DG; Bunni M; Sirotnak FM Cancer Res; 1989 Aug; 49(15):4204-9. PubMed ID: 2743307 [TBL] [Abstract][Full Text] [Related]
10. Accumulation of tetrahydrofolates in human plasma after leucovorin administration. Bunni MA; Rembiesa BM; Priest DG; Sahovic E; Stuart R Cancer Chemother Pharmacol; 1989; 23(6):353-7. PubMed ID: 2785439 [TBL] [Abstract][Full Text] [Related]
11. Folates in plasma and bile of man after feeding folic acid--3H and 5-formyltetrahydrofolate (folinic acid). Pratt RF; Cooper BA J Clin Invest; 1971 Feb; 50(2):455-62. PubMed ID: 4992993 [TBL] [Abstract][Full Text] [Related]
12. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro. Matherly LH; Czajkowski CA; Muench SP; Psiakis JT Cancer Res; 1990 Jun; 50(11):3262-9. PubMed ID: 2139802 [TBL] [Abstract][Full Text] [Related]